Despite the covid-19 crisis and no mega-rounds of investment in 2020, Biotech start-ups are back at the top!
Swiss Biotech startups collected more than CHF 800 million in 2020, an increase of 31% compared to 2019. This is linked to the fact that innovation in drug development is taking place in the long term and, to the constant growing worldwide trend of investments in Biotech.

Discover how our technology can make drug development more efficient, safer, and more personalized.